Phase IIIb data backs Daiichi Sankyo's Lixiana in atrial fibrillation patients undergoing cardioversion

30 August 2016
daiichi-sankyo-logo-big

Japanese drug major Daiichi Sankyo (TYO: 4568) has announced results from the global Phase IIIb ENSURE-AF study of Lixiana (edoxaban) in patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion.

Data demonstrated that the oral, once-daily drug, which is known as Savaysa in the USA, met the study’s primary endpoints, showing comparable efficacy and safety to well-managed enoxaparin/warfarin for the prevention of stroke and other blood clot complications.

The results from ENSURE-AF were presented on Tuesday at the European Society of Cardiology (ESC) Congress 2016 in Rome, and published in The Lancet. They show that Lixiana may be an effective and well-tolerated alternative to conventional treatment with enoxaparin and a vitamin K antagonist (VKA), and may allow prompt cardioversion to be performed with transoesophageal echocardiography (TEE)

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical